Radoslav Chekerov

Stable expansion of high‐grade serous ovarian cancer organoids requires a low‐Wnt environment

Karen Hoffmann, Hilmar Berger, Hagen Kulbe et al. · The EMBO Journal · 2020 · 248 citations · Full text

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García et al. · The Lancet · 2023 · 175 citations

Oncology, Cervical Cancer, Metronomic Therapy +6

The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma — Analysis of patient data in the prospective OVCAD study

Gerda Hofstetter, Nicole Concin, Radoslav Chekerov et al. · Gynecologic Oncology · 2013 · 133 citations

Prognostic Evaluation, Surgical Oncology, Patient Data +12

Prognostic Value of Residual Tumor Size in Patients With Epithelial Ovarian Cancer FIGO Stages IIA-IV

Stephan Polterauer, Ignace Vergote, Nicole Concin et al. · International Journal of Gynecological Cancer · 2012 · 109 citations

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Radoslav Chekerov, Felix Hilpert, Sven� Mahner et al. · The Lancet Oncology · 2018 · 108 citations

Oncology, Medicine, Metronomic Therapy +8